Insulin Therapy
5 years after rejection, sotagliflozin for type 1 diabetes gets new FDA panel hearing
Five years after receiving a complete response letter from the agency, Lexicon Pharmaceuticals brought sotagliflozin back before an FDA advisory panel to seek an indication to treat patients with type 1 diabetes and chronic kidney disease.
Insulin Therapy
More than 20% of US adults with type 1 diabetes likely have chronic kidney disease
More than one in five adults in the U.S. with type 1 diabetes also have chronic kidney disease, according to findings from a brief report published in Diabetes Care.
Sustained reduction in HbA1c for adults with type 2 diabetes after starting CGM
ORLANDO — Adults with type 2 diabetes experienced a reduction in HbA1c within 3 months of starting continuous glucose monitoring, regardless of insulin therapy, a presenter reported at the American Diabetes Association Scientific Sessions.
Metformin use during conception does not increase risk for adverse birth outcomes
Maternal and paternal metformin use during conception did not increase the risk for adverse pregnancy outcomes, two studies in Annals of Internal Medicine showed.
Close follow-up, education critical for preventing recurrence of hyperglycemic crises
NEW ORLEANS — A consensus statement on managing diabetic ketoacidosis and hyperosmolar hyperglycemic state for adults with diabetes focuses on preventing recurrence and providing people with the tools to maintain glycemic control.
Q&A: Standards of Care encourages more people with diabetes to use CGM
The 2024 American Diabetes Association Standards of Care put an emphasis on getting continuous glucose monitoring into the hands of more people with diabetes.
As technology improves, increasing CGM access requires education, community support
In 1999, the FDA approved the Medtronic MiniMed as the first continuous glucose monitor for people with diabetes. In the 25 years since that approval, use of diabetes technology has gradually increased.
ONWARDS 5: Weekly insulin therapy guided by app improves glycemic control
Patients with type 2 diabetes who used icodec titrated with the help of an app saw greater reductions in HbA1c compared with once-daily basal insulin analogues dosed per standard clinical practice, a randomized clinical trial showed.
Outpatient endoscopic procedure ‘may be a game changer’ for type 2 diabetes management
A novel endoscopic procedure combined with semaglutide may eliminate the need for insulin while improving glycemic control and metabolic parameters among patients with type 2 diabetes.